| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | CBO2730 |
| Uniprot No | A5I5G4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-275aa |
| 氨基酸序列 | MIINHNLNAMNAHRQMAINTGNNGKAIEKLSSGLRINRAGDDAAGLAISEKMRGQIRGLNQASRNSQDAISLIQTAEGALNETHSILQRMRELTVQAANDTNVTVDRENLQKEVAELQSEINRISSQTQFNTKSLINGAVSKDADAMTFQIGANSGQTIKLTIGSMDAKTLNVDKIKLDDTAANVTKQIATIDNAINSVSKERAKLGANQNRLEHTIANLDNSAENLQAAESRIRDVDMAKEMMNFTKTNILTQAAQAMLAQANQAPQGVLQLLR |
| 预测分子量 | 45.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CBO2730重组蛋白的模拟参考文献示例(注：CBO2730为肉毒梭菌基因编号，实际文献可能需要通过学术数据库核实)：
1. **文献名称**：Cloning and Expression of Recombinant CBO2730 Protein from *Clostridium botulinum*
**作者**：Smith J, et al.
**摘要**：本研究成功克隆并表达了肉毒梭菌CBO2730基因的重组蛋白，通过大肠杆菌表达系统优化了蛋白的可溶性，并利用亲和层析技术纯化获得高纯度蛋白，为后续功能研究奠定基础。
2. **文献名称**：Structural Characterization of CBO2730: A Putative Toxin-associated Protein in Botulism
**作者**：Lee H, et al.
**摘要**：通过X射线晶体学解析了CBO2730重组蛋白的三维结构，发现其具有独特的β-折叠结构域，推测其可能参与肉毒毒素的稳定性或宿主相互作用，但具体功能仍需验证。
3. **文献名称**：Functional Analysis of Recombinant CBO2730 in Bacterial Pathogenicity
**作者**：Garcia R, et al.
**摘要**：利用基因敲除和回补实验证明CBO2730重组蛋白可恢复肉毒梭菌突变株的体外黏附能力，提示其在细菌致病过程中可能起辅助作用。
4. **文献名称**：Immunogenicity Evaluation of CBO2730 as a Potential Vaccine Candidate
**作者**：Wang Y, et al.
**摘要**：在小鼠模型中评估CBO2730重组蛋白的免疫原性，结果显示其能诱导特异性抗体产生，并部分保护动物免受肉毒梭菌感染，提示其作为疫苗组分的潜力。
**注意**：以上为模拟生成的参考文献，实际研究需通过PubMed、Web of Science等平台以关键词“CBO2730 recombinant”或“Clostridium botulinum CBO2730”检索确认。
CBO2730 recombinant protein is a genetically engineered biomolecule derived from the codon-optimized sequence of a native protein, often associated with microbial or viral origins, to enhance expression in heterologous systems. Typically produced in *E. coli* or yeast via recombinant DNA technology, it is purified using affinity chromatography (e.g., His-tag systems) or size-exclusion methods, ensuring high stability and solubility for experimental applications. The protein’s structure may include functional domains critical for ligand binding, enzymatic activity, or immunogenic responses, depending on its biological source.
Originally identified in pathogenic organisms, CBO2730 is hypothesized to play roles in virulence or host-pathogen interactions, making it a target for therapeutic or diagnostic development. In research, it serves as a tool to study protein-protein interactions, immune responses, or as an antigen for antibody production. Its recombinant form overcomes challenges like low native expression or purification complexity.
Potential applications span vaccine design (as an immunogen), drug discovery (enzyme inhibition assays), and diagnostic kits (antigen detection). Studies may explore its efficacy in animal models to validate protective immunity or therapeutic potential. Despite its promise, functional characterization and structural validation (via X-ray crystallography or cryo-EM) remain essential to confirm mechanistic roles and optimize utility.
CBO2730 exemplifies the intersection of bioengineering and translational medicine, offering scalable production for both basic research and biotechnological innovations. Further studies are needed to elucidate its full biological significance and clinical applicability.
×
